Antihemophilic factor, human recombinant: all 26 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)RecruitingNCT07129343Phase 3
- Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)RecruitingNCT06864975Phase 4
- A Study of ADVATE in People With Hemophilia A in IndiaCompletedNCT04985682Phase 4Results posted
- Prospective Biomarkers of Bone Metabolism in Hemophilia ACompletedNCT02306694Phase 3Results posted
- BAX 855 Pediatric StudyCompletedNCT02210091Phase 3Results posted
- Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)CompletedNCT01736475Phase 2/3Results posted
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)CompletedNCT01410227Phase 3Results posted
- Early Prophylaxis Immunologic Challenge (EPIC) StudyTerminatedNCT01376700Phase 3Results posted
- A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT01233258Phase 3Results posted
- Survey of Inhibitors in Plasma-Product Exposed ToddlersCompletedNCT01064284Phase 4Results posted
- Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia ACompletedNCT01029340Phase 3Results posted
- Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for InjectionCompletedNCT00952822Phase 1Results posted
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedNCT00289536Phase 4Results posted
- Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedNCT00243386Phase 4Results posted
- Preventing Inhibitor Recurrence IndefinitelyActive, not recruitingNCT04621916Phase 4
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)CompletedNCT02932618Phase 3
- Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric PatientsCompletedNCT02727647Phase 4
- Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and AdvateCompletedNCT02483208Phase 1
- Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia AStatus unknownNCT02282410Not applicable
- BAX 855 Dose-Escalation Safety StudyCompletedNCT01599819Phase 1
- Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. NaiveWithdrawnNCT01051544Not applicable
- Individually Tailored Prophylaxis in Patients With Severe Hemophilia ATerminatedNCT00995046Not applicable
- Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A SubjectsCompletedNCT00837356Phase 1
- Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedNCT00157105Phase 2/3
- Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedNCT00157053Phase 2/3
- Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedNCT00157040Phase 2/3